KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cme (CME) Notes Payables (2018 - 2025)

Cme has reported Notes Payables over the past 10 years, most recently at $750.0 million for Q1 2025.

  • Quarterly Notes Payables changed 0.09% to $750.0 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $750.0 million through Mar 2025, changed 0.09% year-over-year, with the annual reading at $749.8 million for FY2024, N/A changed from the prior year.
  • Notes Payables was $750.0 million for Q1 2025 at Cme, roughly flat from $749.8 million in the prior quarter.
  • Over five years, Notes Payables peaked at $750.0 million in Q1 2025 and troughed at $14.5 million in Q3 2022.
  • The 5-year median for Notes Payables is $749.4 million (2021), against an average of $529.4 million.
  • Biggest five-year swings in Notes Payables: plummeted 98.06% in 2022 and later surged 4496.93% in 2024.
  • Tracing CME's Notes Payables over 5 years: stood at $749.4 million in 2021, then plummeted by 97.86% to $16.0 million in 2022, then grew by 1.88% to $16.3 million in 2023, then surged by 4500.0% to $749.8 million in 2024, then grew by 0.03% to $750.0 million in 2025.
  • According to Business Quant data, Notes Payables over the past three periods came in at $750.0 million, $749.8 million, and $749.7 million for Q1 2025, Q4 2024, and Q3 2024 respectively.